The proportion of patients with psoriasis was higher in the IL-17 inhibitor group, and although no statistically significant difference was observed, the proportion of patients with a history of uveitis or IBD was numerically higher in the TNF inhibitor group. The gene discussed is IL17A; the disease is inflammatory bowel disease.